Pfizer, BioNTech shares get more data back fax candidate

FILE PHOTO: A man walks past a sign outside Pfizer headquarters in the source of Manhattan in New York City, New York, USA, July 22, 2020. REUTERS / Carlo Allegri / File Photo

(Reuters) – Shares of Pfizer Inc and US-listed shares of partner BioNTech SE rose on Friday after releasing additional data for their experimental coronavirus vaccine and reiterating that they were on track to seek a regulatory review in October.

Pfizer has said several times since June that October was focused on its application and the companies began a major late-stage study last month of the candidate vaccine, one of the few worldwide in later stages of development.

On Thursday, they reported data from previous studies in the early stages of the vaccine, BNT162b2, which showed that the similar immune response induced and had milder side effects than previous data on another candidate.

Pfizer stock, down 1% this year, has been chasing the staggering rise in value of major pharmaceutical companies this year. Moderna and AstraZeneca of Britain are among those who have moved into late-stage trials.

Raymond James European strategist Chris Bailey said the Pfizer / BioNTech release had contributed to a more optimistic mood on stock markets on Friday.

Pfizer shares rose 1% while those of BioNTech were 6% higher before the clock.

Report of Manas Mishra in Bengaluru; edited by Patrick Graham

Our standards:The Thomson Reuters Trust Principles.